← All trials
NCT06954441
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2025
- Primary completion
- Sep 27, 2026
- Completion date
- Feb 27, 2027
- First posted
- May 1, 2025
- Last posted
- Aug 22, 2025
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.Lead sponsor
- Hospital do CoracaoOfficial
- Hospital do CoracaoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.